AtriCure Company Insiders

ATRC Stock  USD 23.17  0.56  2.48%   
AtriCure's insiders are aggressively selling. The analysis of insiders' sentiment of trading AtriCure stock suggests that all insiders are panicking at this time. AtriCure employs about 1.2 K people. The company is managed by 27 executives with a total tenure of roughly 221 years, averaging almost 8.0 years of service per executive, having 44.44 employees per reported executive.
Michael Carrel  CEO
CEO and President and Director
Richard Johnston  Chairman
Independent Chairman of the Board

AtriCure's Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-04-01Justin J NozneskyDisposed 1500 @ 30.39View
2024-03-18Karl S DahlquistDisposed 1885 @ 32.16View
2024-03-12Justin J NozneskyDisposed 1500 @ 36.72View
2024-03-05Karl S DahlquistDisposed 8231 @ 37.36View
2023-11-01Karl S DahlquistDisposed 1248 @ 34.43View
2023-07-26Karl S DahlquistDisposed 3417 @ 57.09View
2023-06-08Karen PrangeDisposed 713 @ 47.89View
2023-06-06Karl S DahlquistDisposed 1422 @ 47.03View
2023-05-26Maggie YuenDisposed 4313 @ 47.04View
Monitoring AtriCure's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.

AtriCure's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with AtriCure's future performance. Based on our forecasts, it is anticipated that AtriCure will maintain a workforce of about 1200 employees by May 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

AtriCure's latest congressional trading

Congressional trading in companies like AtriCure, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in AtriCure by those in governmental positions are based on the same information available to the general public.
2021-06-08Representative Josh GottheimerAcquired Under $15KVerify
2020-04-30Representative Gilbert CisnerosDisposed Under $15KVerify

AtriCure Management Team Effectiveness

The company has return on total asset (ROA) of (0.0324) % which means that it has lost $0.0324 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.066) %, meaning that it created substantial loss on money invested by shareholders. AtriCure's management efficiency ratios could be used to measure how well AtriCure manages its routine affairs as well as how well it operates its assets and liabilities. As of April 29, 2024, Return On Tangible Assets is expected to decline to -0.1. In addition to that, Return On Capital Employed is expected to decline to -0.06. At present, AtriCure's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 365.1 M, whereas Other Assets are forecasted to decline to 0.95.
As of April 29, 2024, Common Stock Shares Outstanding is expected to decline to about 24.2 M. The current year's Net Loss is expected to grow to about (39.7 M)

AtriCure Workforce Comparison

AtriCure is rated second in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 7,767. AtriCure retains roughly 1,200 in number of employees claiming about 15% of equities under Health Care industry.

AtriCure Profit Margins

The company has Profit Margin (PM) of (0.08) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.12) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.12.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.580.7449
Significantly Down
Very volatile

AtriCure Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AtriCure insiders, such as employees or executives, is commonly permitted as long as it does not rely on AtriCure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, AtriCure insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
1.5
18
12
 378,137 
 118,157 
2023-12-01
0.5
1
2
 98.00 
 11,248 
2023-06-01
2.8
14
5
 26,084 
 11,865 
2023-03-01
1.7
17
10
 331,011 
 107,373 
2022-12-01
3.0
3
1
 1,488 
 6,000 
2022-09-01
1.0
1
1
 15,000 
 5,191 
2022-06-01
4.3333
13
3
 46,812 
 3,485 
2022-03-01
0.8125
13
16
 169,337 
 128,297 
2021-12-01
0.625
5
8
 481.00 
 22,219 
2021-06-01
1.0435
24
23
 113,472 
 186,791 
2021-03-01
0.6538
17
26
 236,678 
 530,260 
2020-12-01
0.5417
13
24
 238,065 
 515,481 
2020-09-01
0.2
1
5
 35,310 
 26,909 
2020-06-01
1.5
18
12
 118,795 
 204,000 
2020-03-01
0.4524
19
42
 414,351 
 1,015,232 
2019-12-01
1.2
6
5
 13,704 
 45,145 
2019-09-01
0.3333
3
9
 26,954 
 120,808 
2019-06-01
1.7143
12
7
 50,223 
 73,230 
2019-03-01
0.6667
8
12
 114,434 
 215,512 
2018-06-01
2.3333
14
6
 64,792 
 29,415 
2018-03-01
0.7692
10
13
 271,177 
 171,604 
2017-12-01
1.6667
5
3
 4,946 
 5,400 
2017-09-01
0.8
4
5
 155,000 
 48,000 
2017-06-01
2.0
22
11
 149,151 
 166,224 
2017-03-01
0.6154
8
13
 338,938 
 79,448 
2016-12-01
0.5833
7
12
 61,783 
 64,823 
2016-09-01
0.5
2
4
 18,000 
 29,000 
2016-06-01
7.0
14
2
 103,752 
 10,199 
2016-03-01
0.6429
9
14
 505,000 
 120,431 
2015-12-01
0.6364
7
11
 26,225 
 59,161 
2015-06-01
1.5833
19
12
 128,198 
 87,159 
2015-03-01
0.5652
13
23
 358,288 
 195,321 
2014-12-01
0.5714
4
7
 1,718 
 39,322 
2014-06-01
3.5
14
4
 84,264 
 51,029 
2014-03-01
1.4
21
15
 729,431 
 207,577 
2013-12-01
0.3333
3
9
 3,656 
 169,056 
2013-09-01
0.2727
3
11
 60,000 
 100,000 
2013-06-01
0.6471
11
17
 83,832 
 201,012 
2013-03-01
0.3529
6
17
 155,922 
 96,405 
2012-12-01
1.0556
19
18
 699,887 
 120,020 
2012-09-01
2.3
23
10
 42,211 
 366,389 
2012-06-01
0.5455
18
33
 320,596 
 1,776,791 
2012-03-01
0.5455
12
22
 249,900 
 54,667 
2011-12-01
0.3077
4
13
 6,321 
 72,705 
2011-06-01
0.92
23
25
 216,299 
 407,775 
2011-03-01
1.5208
73
48
 700,257 
 357,773 
2010-12-01
4.3333
39
9
 167,288 
 51,021 
2010-09-01
0.1111
1
9
 3,720 
 23,126 
2010-06-01
3.6667
11
3
 78,293 
 9,844 
2010-03-01
3.75
15
4
 364,800 
 8,108 
2009-12-01
1.2857
9
7
 32,137 
 4,204 
2009-09-01
17.0
17
1
 351,252 
 10,000 
2009-06-01
1.2308
16
13
 93,283 
 112,580 
2008-12-01
25.0
25
1
 71,600 
 2,000 
2008-06-01
1.5
42
28
 262,000 
 98,343 
2008-03-01
0.2222
2
9
 53,000 
 57,667 
2007-06-01
7.5
15
2
 315,537 
 10,000 
2007-03-01
0.4
2
5
 92,104 
 217,104 
2006-09-01
0.6
12
20
 134,892 
 173,223 
2006-06-01
1.75
7
4
 170,000 
 42,565 
2006-03-01
1.0
1
1
 10,000 
 28,506 
2005-12-01
1.6667
5
3
 193,157 
 18,419 
2005-09-01
0.7419
23
31
 5,594,284 
 1,690,878 

AtriCure Notable Stakeholders

An AtriCure stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AtriCure often face trade-offs trying to please all of them. AtriCure's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AtriCure's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael CarrelCEO and President and DirectorProfile
Richard JohnstonIndependent Chairman of the BoardProfile
Patricia KennedyVice President General Manager - InternationalProfile
Justin NozneskySenior Vice President Marketing and Business DevelopmentProfile
Andrew WadeCFO, Senior Vice PresidentProfile
Salvatore PriviteraCTOProfile
Andrew LuxSr. VP of Operations and Quality AssuranceProfile
Regina GrovesIndependent DirectorProfile
Scott DrakeIndependent DirectorProfile
Mark CollarIndependent DirectorProfile
Mark LanningIndependent DirectorProfile
Robert WhiteIndependent DirectorProfile
Sven WehrweinIndependent DirectorProfile
Elizabeth KrellIndependent DirectorProfile
Michael HoovenFounder and DirectorProfile
Karen RobardsIndependent DirectorProfile
Kristine JohnsonIndependent DirectorProfile
Deborah YountChief OfficerProfile
JD CCEPChief OfficerProfile
CCEP CCEPChief OfficerProfile
Valerie StorchWillhausVice CommunicationsProfile
Angela CPAChief OfficerProfile
Tonya SPHRVP HRProfile
Vinayak DoraiswamyChief OfficerProfile
Salvatore JDChief OfficerProfile
Douglas SeithChief OfficerProfile
Amalio MDEx OfficerProfile

About AtriCure Management Performance

The success or failure of an entity such as AtriCure often depends on how effective the management is. AtriCure management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AtriCure management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AtriCure management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.1)(0.10)
Return On Capital Employed(0.06)(0.06)
Return On Assets(0.05)(0.05)
Return On Equity(0.07)(0.07)
The data published in AtriCure's official financial statements usually reflect AtriCure's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of AtriCure. For example, before you start analyzing numbers published by AtriCure accountants, it's critical to develop an understanding of what AtriCure's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of AtriCure's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AtriCure's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in AtriCure's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AtriCure. Please utilize our Beneish M Score to check the likelihood of AtriCure's management manipulating its earnings.

AtriCure Workforce Analysis

Traditionally, organizations such as AtriCure use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AtriCure within its industry.

AtriCure Manpower Efficiency

Return on AtriCure Manpower

Revenue Per Employee332.7K
Revenue Per Executive14.8M
Net Loss Per Employee25.4K
Net Loss Per Executive1.1M
Working Capital Per Employee159.7K
Working Capital Per Executive7.1M
When determining whether AtriCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AtriCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atricure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atricure Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for AtriCure Stock analysis

When running AtriCure's price analysis, check to measure AtriCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AtriCure is operating at the current time. Most of AtriCure's value examination focuses on studying past and present price action to predict the probability of AtriCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AtriCure's price. Additionally, you may evaluate how the addition of AtriCure to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Equity Valuation
Check real value of public entities based on technical and fundamental data
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Is AtriCure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AtriCure. If investors know AtriCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AtriCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.66)
Revenue Per Share
8.621
Quarterly Revenue Growth
0.21
Return On Assets
(0.03)
Return On Equity
(0.07)
The market value of AtriCure is measured differently than its book value, which is the value of AtriCure that is recorded on the company's balance sheet. Investors also form their own opinion of AtriCure's value that differs from its market value or its book value, called intrinsic value, which is AtriCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AtriCure's market value can be influenced by many factors that don't directly affect AtriCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AtriCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if AtriCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AtriCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.